JP2021533204A5 - - Google Patents

Info

Publication number
JP2021533204A5
JP2021533204A5 JP2021529521A JP2021529521A JP2021533204A5 JP 2021533204 A5 JP2021533204 A5 JP 2021533204A5 JP 2021529521 A JP2021529521 A JP 2021529521A JP 2021529521 A JP2021529521 A JP 2021529521A JP 2021533204 A5 JP2021533204 A5 JP 2021533204A5
Authority
JP
Japan
Prior art keywords
antibody
btn3a
pharmaceutical composition
seq
isolated anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021529521A
Other languages
English (en)
Japanese (ja)
Other versions
JP7401166B2 (ja
JP2021533204A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/070693 external-priority patent/WO2020025703A1/en
Publication of JP2021533204A publication Critical patent/JP2021533204A/ja
Publication of JP2021533204A5 publication Critical patent/JP2021533204A5/ja
Priority to JP2023204480A priority Critical patent/JP7825605B2/ja
Application granted granted Critical
Publication of JP7401166B2 publication Critical patent/JP7401166B2/ja
Priority to JP2025160594A priority patent/JP2026016397A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021529521A 2018-08-01 2019-07-31 抗btn3a抗体及びがん又は感染性障害の処置におけるその使用 Active JP7401166B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023204480A JP7825605B2 (ja) 2018-08-01 2023-12-04 抗btn3a抗体及びがん又は感染性障害の処置におけるその使用
JP2025160594A JP2026016397A (ja) 2018-08-01 2025-09-26 抗btn3a抗体及びがん又は感染性障害の処置におけるその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18306050 2018-08-01
EP18306050.8 2018-08-01
EP19153992.3 2019-01-28
EP19153992 2019-01-28
PCT/EP2019/070693 WO2020025703A1 (en) 2018-08-01 2019-07-31 Anti-btn3a antibodies and their use in treating cancer or infectious disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023204480A Division JP7825605B2 (ja) 2018-08-01 2023-12-04 抗btn3a抗体及びがん又は感染性障害の処置におけるその使用

Publications (3)

Publication Number Publication Date
JP2021533204A JP2021533204A (ja) 2021-12-02
JP2021533204A5 true JP2021533204A5 (enExample) 2022-08-05
JP7401166B2 JP7401166B2 (ja) 2023-12-19

Family

ID=67470408

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021529521A Active JP7401166B2 (ja) 2018-08-01 2019-07-31 抗btn3a抗体及びがん又は感染性障害の処置におけるその使用
JP2023204480A Active JP7825605B2 (ja) 2018-08-01 2023-12-04 抗btn3a抗体及びがん又は感染性障害の処置におけるその使用
JP2025160594A Pending JP2026016397A (ja) 2018-08-01 2025-09-26 抗btn3a抗体及びがん又は感染性障害の処置におけるその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023204480A Active JP7825605B2 (ja) 2018-08-01 2023-12-04 抗btn3a抗体及びがん又は感染性障害の処置におけるその使用
JP2025160594A Pending JP2026016397A (ja) 2018-08-01 2025-09-26 抗btn3a抗体及びがん又は感染性障害の処置におけるその使用

Country Status (22)

Country Link
US (3) US11987631B2 (enExample)
EP (2) EP3830119B1 (enExample)
JP (3) JP7401166B2 (enExample)
KR (1) KR102949202B1 (enExample)
CN (2) CN118459590A (enExample)
AU (2) AU2019312831B2 (enExample)
BR (1) BR112021001776A2 (enExample)
CA (2) CA3275403A1 (enExample)
CL (1) CL2021000258A1 (enExample)
DK (1) DK3830119T3 (enExample)
ES (1) ES3060430T3 (enExample)
FI (1) FI3830119T3 (enExample)
HR (1) HRP20260034T1 (enExample)
IL (1) IL280563B2 (enExample)
LT (1) LT3830119T (enExample)
MX (1) MX2021001268A (enExample)
RS (1) RS67711B1 (enExample)
SG (1) SG11202101038SA (enExample)
SI (1) SI3830119T1 (enExample)
SM (1) SMT202600072T1 (enExample)
WO (1) WO2020025703A1 (enExample)
ZA (1) ZA202100819B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018010295A (es) * 2016-02-26 2019-06-06 Inst Nat Sante Rech Med Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2021001268A (es) * 2018-08-01 2021-09-08 Imcheck Therapeutics Sas Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
WO2022266539A2 (en) * 2021-06-18 2022-12-22 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
TW202313695A (zh) 2021-09-15 2023-04-01 法商感應檢查療法公司 抗btn3a抗體在製備用於治療腫瘤的藥物的用途
WO2023052541A1 (en) 2021-09-30 2023-04-06 Imcheck Therapeutics Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
CA3234598A1 (en) 2021-10-27 2023-05-04 Daniel Olive Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
EP4482859A1 (en) 2022-02-27 2025-01-01 Boehringer Ingelheim International GmbH Bispecific antibodies against cd277 and a tumor-antigen
WO2024074498A1 (en) 2022-10-04 2024-04-11 Imcheck Therapeutics Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
IL322506A (en) 2023-02-23 2025-10-01 Imcheck Therapeutics Combinations of BTN3A activating antibody and immune checkpoint inhibitors
TW202506731A (zh) 2023-04-27 2025-02-16 法商感應檢查療法公司 治療多重抗藥性細菌感染之方法
EP4731681A1 (en) 2023-06-23 2026-04-29 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
WO2025031287A1 (zh) * 2023-08-04 2025-02-13 江苏恒瑞医药股份有限公司 Btn3a结合蛋白及其医药用途
WO2025223116A1 (en) * 2024-04-24 2025-10-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-btn3a antibodies and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CN101370830A (zh) * 2005-09-26 2009-02-18 米德列斯公司 抗cd70的人单克隆抗体
EP3002296B1 (en) 2009-03-17 2020-04-29 Université d'Aix-Marseille Btla antibodies and uses thereof
BR112012007875A2 (pt) 2009-07-31 2016-11-22 Medarex Inc anticorpos totalmente humanos para btla
JP5781514B2 (ja) 2009-09-06 2015-09-24 プロトエービー リミテッド Hsp65由来のペプチド6に特異的なヒト化抗体、その方法及び使用
RS57215B1 (sr) 2010-07-15 2018-07-31 Adheron Therapeutics Inc Humanizovana antitela koja ciljaju ec1 domen kadherina-11 i kompozicije i postupci koji su u vezi sa njima
US20150353643A1 (en) * 2013-09-24 2015-12-10 Universite De La Mediterranee - Aix-Marseille Ii Anti-cd277 antibodies and uses thereof
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
TWI734975B (zh) 2014-06-27 2021-08-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
IL297773B2 (en) * 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
MX2018010295A (es) 2016-02-26 2019-06-06 Inst Nat Sante Rech Med Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2021001268A (es) * 2018-08-01 2021-09-08 Imcheck Therapeutics Sas Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
TW202313695A (zh) * 2021-09-15 2023-04-01 法商感應檢查療法公司 抗btn3a抗體在製備用於治療腫瘤的藥物的用途

Similar Documents

Publication Publication Date Title
JP2021533204A5 (enExample)
US10881741B2 (en) Single chain Fc fusion proteins
TWI734722B (zh) 使用胃抑肽受體(gipr)結合蛋白與glp-1促效劑之組合來治療或改善代謝病症之方法
JP2638652B2 (ja) カケクチンと反応するモノクロナール抗体
CN103619878B (zh) 结合血清白蛋白的蛋白
JP2023011661A (ja) 標的化キメラタンパク質及びその使用
EP3119806B1 (en) Il-21 antibodies
RU2651776C2 (ru) Биспецифические антитела против cd3*cd19
CN103079586B (zh) G‑csf二聚体在治疗嗜中性粒细胞减少症中的应用
CA2663042A1 (en) Serum albumin binding proteins with long half-lives
FI3830119T3 (fi) Anti-btn3a-vasta-aineita ja niiden käyttö syövän tai infektiosairauksien hoitamisessa
JP7702445B2 (ja) 免疫調節融合タンパク質
JP6192862B2 (ja) Fc融合高親和性IgE受容体α鎖
TW201520226A (zh) 泛-elr+cxc趨化因子抗體
KR20180084045A (ko) 비형 간염 표면 항원에 대한 항체 및 그의 용도
TW202035459A (zh) 抗人類Fn14抗體
JP7830450B2 (ja) 修飾されたil-2分子及びその用途
WO2019148405A1 (zh) IL-4Rα抗体及其用途
JP2017524675A5 (enExample)
JP2023542049A (ja) インターロイキン-2ムテイン及びその使用
JP2022527542A5 (enExample)
WO2024017281A1 (zh) 多特异性抗体及其用途
JP7606173B2 (ja) I型インターフェロンの中和型Fc融合タンパク質及びその使用
RU2021104977A (ru) Антитела против btn3a и их применение при лечении рака или инфекционных заболеваний
CN1291998C (zh) Nkg2d受体的配体及其应用